Liquid Biopsy Summit
TD Cowen issued its first report on liquid biopsy ten years ago. In it, we introduced the concept, highlighted the early entrants, and evaluated the opportunity. Today, commercial traction (in particular for oncology) is material with a handful of players (mostly public) dominating. Additionally, many new companies are expected to enter leveraging new innovation & strategies.
What will the next 10+ years look like? Please join the TD Cowen team and an array of liquid biopsy leaders and innovators for a one-day summit to answer that question.
*Cowen conferences and events are intended for institutional clients and corporate clients of the firm. They are not open to media or retail investors.